Astrana Health vs ICF International
ASTH and ICFI side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASTH and ICFI compare
Astrana Health is the larger company, worth 1.3 times as much as ICF International ($1.8B against $1.4B).
On earnings, ICF International is cheaper: it trades at 16.4× trailing earnings, against 40.1× for Astrana Health.
Astrana Health grew revenue faster over the last twelve months (58.9% versus −7.9% for ICF International).
ICF International keeps more of each dollar of sales as profit, with a net margin of 4.9% compared with 1.1% at Astrana Health.
ICF International pays a dividend yielding 0.71%; Astrana Health does not pay one.
ICF International scores higher on the StockData Score (20 against 8 for Astrana Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASTH | ICFI |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $1.4B |
| Share price | $32.87 | $79.42 |
| Change, 1 year | 50.0% | 0.23% |
| Change, 5 years | −65.2% | −20.8% |
| Beta (5Y) | 1.00 | 1.41 |
| Employees | 3,000 | 8,400 |
| StockData Score | ||
| Total score | 8 | 20 (better) |
| Valuation score | 1 | 6 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 40.1× | 16.4× (better) |
| P/S | 0.5× (better) | 0.8× |
| P/B | 2.2× | 1.4× (better) |
| EV/EBITDA | 14.5× | 9.3× (better) |
| P/FCF | 19.4× | 7.2× (better) |
| PEG | – | 1.21 |
| FCF yield | 5.2% | 13.9% (better) |
| Fair value | $26.41 | $119.66 |
| Margin of safety | −24.5% | 33.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 58.9% (better) | −7.9% |
| Revenue growth, 5Y average | 35.9% (better) | 4.4% |
| Net income growth (TTM) | 60.5% (better) | −17.8% |
| EPS growth (TTM) | 57.7% (better) | −16.0% |
| EPS growth, 5Y average | −14.6% | 11.5% (better) |
| Profitability | ||
| Gross margin | 10.5% | 37.2% (better) |
| Operating margin | 2.6% | 7.8% (better) |
| Net margin | 1.1% | 4.9% (better) |
| FCF margin | 2.5% | 10.9% (better) |
| Return on equity | 5.1% | 8.6% (better) |
| Return on invested capital | 6.0% | 7.7% (better) |
| Financial health | ||
| Debt / equity | 1.13 | 0.39 (better) |
| Net debt / EBITDA | 3.28 | 2.05 (better) |
| Interest coverage | 1.5× | 4.9× (better) |
| Current ratio | 1.23 | 1.39 (better) |
| Altman Z-score | 2.78 (better) | 2.66 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.71% |
| Payout ratio | 4.6% | 11.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | 0.97% | 3.2% (better) |
| Shareholder yield | 0.97% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 57.7% | 102% |
| Held by insiders | 30.7% | 1.8% |
| Insider net buying, 12 months | – | −$1.4M |
| Short interest, % of float | 7.8% | 3.6% |
Go deeper
- ASTH stock overview
- ASTH income statement
- ASTH valuation and score
- ICFI stock overview
- ICFI income statement
- ICFI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.